ReviewCurrent stem cell research & therapy2026
Mesenchymal Stem Cell-derived Exosomes in the Treatment of End-stage Liver Disease.
Review in Current stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
End-stage liver disease (ESLD) poses a significant threat to human health due to its high mortality rate. Although liver transplantation represents the most effective treatment modality, its application is limited by donor scarcity and prohibitive costs, thereby necessitating the development of innovative and efficacious therapeutic strategies. Within the realm of regenerative medicine, stem cell therapy has emerged as a promising alternative for ESLD treatment, with mesenchymal stem cells (MSCs) being at the forefront due to their exceptional multifunctional differentiation and self-renewal capabilities. Nonetheless, safety concerns, including the potential risk of tumorigenesis associated with MSCs, remain inadequately addressed. Recent evidence indicates that the therapeutic effects of MSCs are primarily mediated through paracrine mechanisms, with MSC-derived exosomes (MSC-Exos) serving as the principal effector mediators. The utilization of exosomes alone for therapeutic purposes not only preserves the beneficial effects of MSCs but also mitigates risks such as tumorigenic potential. Over the past few years, MSC-Exos have demonstrated significant ad-vancements across various medical disciplines, including cardiology, neurology, and gastroenterology. This review outlines the key mechanisms and recent progress in utilizing MSC-Exos in treating end-stage liver disease, seeking to highlight their unique therapeu- tic role.
Indexed as
Identifiers
40574407What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.